

The Histone Deacetylase Inhibitor LAQ-824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide

Roberto R. Rosato, Sonia C. Maggio, Jorge A. Almenara, Shawn G. Payne, Peter Atadja, Sarah Spiegel, Paul Dent, Steven Grant.

Departments of Medicine (R.R.R., S.C.M., J.A.A, S.G.), Radiation Oncology (P.D.) and Biochemistry (S.G.P., S.S., S.G.), Virginia Commonwealth University, Richmond, VA, 23298; and Department of Oncology, Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.

Running title: Mechanism of HDACI LAQ824-induced apoptosis

Number of text pages: 32

Number of tables: 0

Number of figures: 7

Number of references: 40

Number of words in the Abstract: 225

Number of words in the Introduction: 582

Number of words in the Discussion: 1338

Abbreviations: HDACI, histone deacetylase inhibitor; ROS, reactive oxygen species; HAT, histones acetyltransferases; c-FLIP, FLICE-inhibitory protein; PI, propidium iodide; PARP, poly(ADP-ribose)polymerase; AIF, apoptosis inducing factor; $\Delta\psi_m$, mitochondrial membrane potential; PAGE, polyacrylamide gel electrophoresis; DiOC₆, 3,3-dihexyloxycarbocyanine.

Corresponding author: Dr. Steven Grant

Medical College of Virginia,

Virginia Commonwealth University

MCV Station Box 230

Richmond, VA – 23298

Phone: 1(804) 828-5211

Fax: 1(804) 828-8079

E-mail: stgrant@hsc.vcu.edu

ABSTRACT

Determinants of differentiation and apoptosis induction by the novel histone deacetylase inhibitor (HDACI) LAQ824 were examined in human leukemia cells (U937 and Jurkat). Exposure of U937 cells to a low concentration of LAQ824 (30 nM) resulted in a delayed (2 hr) increase in ROS, induction of p21^{WAF1/CIP1}, pRb dephosphorylation, growth arrest of cells in G₀/G₁, and differentiation. On the other hand, exposure of cells to a higher concentration of LAQ824 (75 nM) resulted in the early (30 min) generation of ROS, arrest of cells in G₂/M, down-regulation of XIAP (at the transcriptional level) and Mcl-1 (through a caspase-mediated process), the acid-sphingomyelinase-dependent generation of ceramide, and profound mitochondrial injury, caspase activation, and apoptosis. LAQ824-induced lethality in U937 cells did not involve the extrinsic apoptotic pathway nor was it associated with death receptor upregulation; instead, it was markedly inhibited by ectopic expression of Bcl-2, Bcl-x_L, XIAP and Mcl-1. The free radical scavenger N-acetyl cysteine (NAC) blocked LAQ824-mediated ROS generation, mitochondrial injury, Mcl-1 down-regulation, ceramide generation, and apoptosis, suggesting a primary role for oxidative injury in LAQ824 lethality. Together, these findings indicate that LAQ824-induced lethality represents a multifactorial process in which LAQ824-mediated ROS generation is necessary but not sufficient to induce apoptosis, and that the degree of XIAP and Mcl-1 down-regulation as well as ceramide generation determines whether this agent engages a maturation rather than an apoptotic program.

Recently, attention has focused on the role of histone deacetylase inhibitors (HDACIs) as antineoplastic agents, and several of these compounds are currently in various stages of clinical development (Rosato and Grant, 2004). HDACIs comprise a diverse group of agents that act by promoting histone hyperacetylation. Histone acetylation is maintained by the net balance between the opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs), and represents an important mechanism by which chromatin remodeling and transcriptional activity are regulated (Gray and Teh, 2001). The mechanism of action and the basis for selectivity of HDAC inhibitors toward tumor cells have not yet been fully elucidated, but multiple possibilities exist. For example, HDACIs may interfere with cancer cell proliferation and/or survival through modulation of cell cycle traverse, induction of differentiation, or by promoting cell death (i.e., apoptosis) (Rosato and Grant, 2004). In human leukemia cells, HDACIs, when administered at low concentrations, trigger maturation, whereas at higher concentrations, apoptosis ensues (Rosato *et al.*, 2003b; Rosato *et al.*, 2001). The factors which determine whether HDACIs engage apoptosis versus differentiation remain the subject of investigation, but may involve the extent of mitochondrial injury or oxidative damage, up-regulation of death receptors, activation of the extrinsic pathway, interference with Hsp90 function, down-regulation of anti-apoptotic Bcl-2 family members, and the generation of ceramide, among others (Rosato *et al.*, 2003b; Guo *et al.*, 2004; Yu *et al.*, 2002; Maggio *et al.*, 2004; Kurita-Ochiai *et al.*, 2003). Recent reports have suggested that induction of death receptors and perturbations in cellular redox status may underlie the selectivity of these agents toward neoplastic cells (Insinga *et al.*, 2005; Ungerstedt *et al.*, 2005). A variety of compounds with HDAC inhibitory activity have now been identified. Based on their structural features, they have been subdivided into four basic groups: a) short-chain fatty acids (e.g., sodium butyrate, AN-9;

phenylbutyrate; phenylacetate; valproic acid); b) synthetic benzamide derivatives (e.g., MS-275 and CI-994); c) cyclic tetrapeptides (e.g., depsipeptide, trapoxin, apicidin); and d) hydroxamic acids (SAHA, pyroxamide, TSA, oxamflatin, CHPAs; LAQ824) (Rosato and Grant, 2004).

NVP-LAQ824 is a structurally novel cinnamic hydroxamic acid, which exhibits potent *in vitro* activity when administered at submicromolar concentrations (Atadja *et al.*, 2004a). LAQ824 has been shown to induce apoptosis in multiple myeloma cell lines resistant to more conventional therapeutic agents (Catley *et al.*, 2003) and in Bcr/Abl⁺ human leukemia cells resistant to imatinib mesylate (Nimmanapalli *et al.*, 2003). LAQ824 is also active against several additional neoplastic cell types including breast (Fuino *et al.*, 2003), colon, non-small cell lung carcinoma, prostate cancer (Atadja *et al.*, 2004a) and other leukemia cells (Guo *et al.*, 2004). In addition to its direct cytotoxic actions, LAQ824 can sensitize transformed cells to other agents. For example, in breast cancer cells, LAQ824 depleted Her-2 mRNA and protein levels and significantly increased the lethality of trastuzumab, taxotere, gemcitabine and epothilone B (Fuino *et al.*, 2003). In both human SKW6.4 and Jurkat leukemia cells, LAQ824 induced an increase in the expression levels of TRAIL death receptors DR4 and DR5 and down-regulation of c-FLIP (FLICE-inhibitory protein), events which sensitize cells to subsequent TRAIL/Apo2-L exposure (Guo *et al.*, 2004).

Currently, relatively little is known about the factors which determine whether LAQ824 induces a maturation program rather than apoptosis in human leukemia cells. To address this question, we have examined the dose-dependent induction of apoptosis by LAQ824 in human myelomonocytic U937 and Jurkat T-human lymphoblastic leukemia cells. Here we report that low concentrations of LAQ824 trigger cell cycle arrest in G₁, most likely through upregulation of the cyclin-dependent kinase inhibitor p21^{WAF1/CIP1}, the relatively delayed generation of reactive

oxygen species (ROS), and cellular maturation. In contrast, higher concentrations of LAQ824 primarily induce apoptosis, an event associated with early ROS generation, G₂M arrest, induction of mitochondrial injury, down-regulation/cleavage of anti-apoptotic proteins including Bcl-2, Bcl-X_L and Mcl-1, transcriptional repression of XIAP, and the acid sphingomyelinase-dependent generation of the pro-apoptotic lipid second messenger ceramide.

MATERIALS AND METHODS

Cells and cell culture. U937 and Jurkat human leukemia cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured and maintained in logarithmic growth phase in RPMI 1640 medium supplemented with sodium pyruvate, MEM essential vitamins, L-glutamate, penicillin, streptomycin, and 10% FBS (Gibco, Invitrogen, Carlsbad, CA, USA). U937 cells stably overexpressing Bcl-2, Bcl-X_L, FADD-DN or XIAP and their empty-vector counterparts were obtained as reported previously (Cartee *et al.*, 2002; Datta *et al.*, 2000) and maintained as described above in the presence of the corresponding selection antibiotics. All experiments were performed utilizing cells in logarithmic phase growth suspended at 2.5×10^5 cells/ml.

Drugs and Chemicals. LAQ824 was kindly provided by Novartis Pharmaceuticals Inc. (East Hanover, NJ). The pan-caspase inhibitor Boc-D-fmk was purchased from Enzyme System Products (Livermore, CA) and dissolved in DMSO. The ceramide synthesis inhibitors were from Calbiochem (San Diego, CA; GW4869), Biomol (Plymouth Meeting, PA; Fumonisin B1 and Myriocin) and Sigma-Aldrich (St. Louis, MO; Desipramine).

Morphological assessment of apoptosis. Apoptotic cells were evaluated by both morphological assessment of Wright-Giemsa-stained cytospin preparations and by annexin V/propidium iodide (PI) staining as previously described (Almenara *et al.*, 2002). Annexin V/PI (BD-PharMingen, San Diego, CA) analysis of cell death was carried out as per the manufacturer's instructions.

Cell Cycle Analysis. Analysis of cell cycle was made by flow cytometry as previously described (Rosato *et al.*, 2001) using a Becton-Dickinson FACScan flow cytometer and Verity Winlist software (Verity Software, Topsham, ME).

Assessment of Mitochondrial Membrane Potential ($\Delta\psi_m$). At the indicated intervals, cells were harvested and 2×10^5 cells were incubated with 40 nM DiOC₆ for 15 min at 37 °C. Analysis was then carried out on Becton-Dickinson FACScan cytofluorometer. The percentage of cells exhibiting low levels of DiOC₆, reflecting loss of mitochondrial membrane potential, was determined as previously described (Almenara *et al.*, 2002).

Determination of Clonogenicity. Pelleted cells were washed extensively and prepared for soft-agar cloning as described previously (Maggio *et al.*, 2004). Cultures were maintained for 10 to 12 days in a 37°C, 5% CO₂ incubator after which colonies, defined as groups of ≥ 50 cells, were scored.

Surface expression analysis of DR4 and DR5. After treatment, U937 cells (1×10^6) were pelleted, washed with PBS, resuspended and blocked for 30 min with 1% BSA in PBS and then incubated with 1 μ g of antibodies against DR4, DR5, DcR1 or DcR2 (Alexis, San Diego, CA) in 1% BSA in PBS for 30 min, followed by washing with PBS. Finally, cells were incubated with FITC-conjugated goat anti-mouse IgG (DAKO, Denmark) for 30 min. After washes, cells were analyzed on a FACScan flow cytometer.

Western Blot Analysis. Whole cell-pellets were washed twice in PBS, resuspended in PBS, and lysed by the addition of one volume of loading buffer (Invitrogen), as previously described (Almenara *et al.*, 2002). 30 μ g of total proteins per point were separated by 4-12% Bis-Tris NuPAGE precast gel system (Invitrogen) and electro-blotted to nitrocellulose. After incubation with the corresponding primary and secondary antibodies, blots were developed by enhanced chemiluminescence (New England Nuclear; Boston, MA). Where indicated, blots were stripped and reprobbed with antibodies directed against actin. Cytosolic proteins were obtained by employing a previously described technique (Almenara *et al.*, 2002) where the S-100, or cytosolic fraction, was prepared as described with minor modifications. For each condition, 30 μ g of the S-100 fraction was loaded on the gel, and probed with the corresponding antibody.

Antibodies for Western blot analysis. Primary antibodies for the following proteins were used at the designated dilutions: Bcl-XL(1:1000 Trevigen, Gaithersburg, MD); PARP (1:1000; BioMol); pro-caspase 3, cytochrome c; cyclins D₁, A and E; Mcl-1; pRb and underphosphorylated Rb, and XIAP (1:1000, BD-Pharmingen); Bcl-2 (1:2000; DAKO, Glostrup, Denmark); caspase 8 (1:2000 Alexia Corporation, San Diego, CA); Bid (1:1000; Cell Signaling, Beverly, MA); actin (1:2000; Sigma-Aldrich Chemicals); Smac/DIABLO and AIF (1:1000, Santa Cruz, Santa Cruz, CA). Secondary antibodies conjugated to horseradish peroxidase were obtained from Kirkegaard and Perry Laboratories, Inc. (Gaithersburg, MD).

Ceramide determination. Ceramide was assayed as described previously (Maggio *et al.*, 2004). Briefly, after various treatments, lipids were extracted, and mass amounts of ceramide in cellular extracts were measured by the diacylglycerol kinase enzymatic method. Ceramide levels were normalized to total phospholipids present in the extracts.

Real-Time Reverse Transcriptase-Polymerase Chain Reaction. Experiments were performed employing the ABI Prism® 7900 Sequence Detection System (Applied Biosystems, Foster City, CA)) using the TaqMan® One Step PCR Master Mix Reagents Kit (P/N: 4309169) as described previously (Rosato *et al.*, 2004).

Statistical analysis. The significance of differences between experimental conditions was determined using the student's T-test for unpaired observations. To assess the interaction between agents, Median Dose Analysis (Maggio *et al.*, 2004) was used with a commercially available software program (CalcuSyn; Biosoft, Ferguson, MO). The combination index (CI) was calculated for a 2-drug combination involving a fixed concentration ratio. Using these methods, CI values less than 1.0 indicate a synergistic interaction.

RESULTS

LAQ824 induces concentration-dependent growth arrest or cell death in human leukemia cells. While concentrations of LAQ824 ≤ 10 nM had no effect on the number of cells compared to controls, exposure of to 30 nM to 75 nM LAQ824 induced partial to essentially complete cell growth inhibition respectively (Figure 1A). A marked increase in apoptosis was noted at LAQ824 concentrations ≥ 50 nM, with maximal effects observed following 48 hr exposure to 75 nM LAQ824. In contrast, LAQ824 concentrations ≤ 30 nM resulted in minimal toxicity (Figure 1B). A clear increase in the percentage of dead cells 24 hr after treatment with 75 nM LAQ82 was noted (data not shown), which correlated with cleavage/activation of Bid, caspases-3 and -8 and PARP degradation (Figure 1C). Results in Jurkat T-human lymphoblastic leukemia cells were similar i.e., cell growth inhibition at lower drug concentrations (20nM) and cell death at higher LAQ824 concentrations (50nM; data not shown).

A low concentration of LAQ824 (30 nM) induced an accumulation of cells in G_0/G_1 at 48 hr (57.4 ± 2.6 vs. $41.2 \pm 2.1\%$; $P < 0.01$), a decline in the S-phase fraction (31.9 ± 1.4 vs. $46.8 \pm 2.4\%$; $P < 0.01$) and no changes in the G_2/M population. In contrast, G_0/G_1 arrest was not readily apparent in cells exposed to 75 nM LAQ824, as the large majority of cells were apoptotic by 48 hr. Notably, cells exposed to a lethal LAQ824 concentration displayed a large accumulation in G_2M at 24 h (e.g., $39.5 \pm 1.8 \%$), whereas this was not observed in cells exposed to 30 nM LAQ824 (data not shown). Western blot analysis revealed a robust concentration-dependent increase of the CDK-inhibitor $p21^{WAF1/CIP1}$ accompanied by increased levels of the hypophosphorylated forms of pRb (Figure 1D). Bands corresponding to pRb cleavage fragments were also noted, particularly at higher LAQ824 concentrations. Significantly, 30 nM LAQ824 induced a pronounced increase in the expression of the maturation markers CD11a and CD11b, whereas no changes were observed in cells exposed to 75 nM LAQ824 (Fig. 1E). Both differentiation and apoptosis may limit colony formation; furthermore, the extent of apoptosis does not necessarily correlate with loss of clonogenicity (Yin and Schimke, 1995). Analysis of clonogenic survival showed a marked reduction in clonogenicity in cells exposed to 30nM LAQ824 (i.e., from 28.3 to 21.3 % of controls for 24 or 72h exposure intervals respectively), effects that were more pronounced in cells treated with 75 nM LAQ824 (i.e., 3.5 or 0.04% of control values for 24 or 72h exposure intervals respectively; Fig. 1F). Thus, despite exerting similar effects on $p21^{WAF1/CIP1}$ and pRb, the antiproliferative activity of a low concentration of LAQ824 stems primarily from cell cycle arrest in G_0/G_1 and cellular maturation, whereas higher LAQ824 concentrations largely reflect caspase activation and apoptosis.

LAQ824-induced cell death does not involve activation of the extrinsic, receptor-mediated apoptotic pathway in U937 cells. Recently, LAQ824 has been shown to enhance the

expression of death receptors DR4 and DR5 in both Jurkat T-lymphoblastic and SKW6.4 B-lymphoblastic leukemia cells (Guo *et al.*, 2004). To determine whether LAQ824 lethality in U937 cells involved a similar mechanism, U937 and Jurkat cells were treated with 30 nM or 75 nM LAQ824 for 24 h in the presence or absence of either anti-TRAIL or anti FAS-L antibodies. LAQ824-induced lethality was blocked by the anti-TRAIL antibody in Jurkat cells (Fig. 2A); in contrast, no inhibitory effects were observed in U937 cells nor were changes observed in either cell line following co-incubation with anti-FAS-L antibody. Analysis of DR5 expression by flow cytometry demonstrated a clear concentration-dependent increase in DR5 expression in Jurkat cells, and consistently, no changes in U937 cells (Fig. 2B), suggesting that LAQ824-mediated up-regulation of the death receptor pathway represents a cell type-specific phenomenon and is unlikely to be involved in LAQ824 lethality in U937 cells.

Exposure of U937 cells to a lethal concentration of LAQ824 results in pronounced mitochondrial injury and down-regulation of anti-apoptotic proteins. As shown in Fig. 3A, 75 nM LAQ824 induced a marked time-dependent loss of mitochondrial membrane potential ($\Delta\Psi_m$) beginning at 16 hours of drug exposure, whereas 30 nM LAQ824 had little effect. Loss of $\Delta\Psi_m$ was accompanied by cytoplasmic release of cytochrome c, AIF and Smac/DIABLO following exposure to 75 nM LAQ824, whereas effects were much less pronounced in cells exposed to 30 nM LAQ824 (Fig. 3B). Furthermore, exposure to 75 nM LAQ824 for 48 hr resulted in a Bcl-2 cleavage product, which has been associated with pro-apoptotic activity (Cheng *et al.*, 1997), and down-regulation of Bcl-xL and Mcl-1 (Fig. 3C). Levels of XIAP were markedly reduced after 24 h of drug exposure as well and essentially absent by 48 h. Furthermore, ectopic expression of either Bcl-2 or Bcl-xL (Rosato *et al.*, 2003a) significantly protected U937 cells from LAQ824-mediated lethality at both 24 and 48 hr ($P < 0.01$; Figure

3D). Together, these findings indicate that in U937 cells, exposure to a lethal concentration of LAQ824 (75 nM) primarily induces apoptosis via the intrinsic, mitochondrial pathway.

Generation of reactive oxygen species (ROS) plays a critical functional role in LAQ824-mediated lethality. The generation of ROS has been shown to represent a primary event in the lethality of several HDACIs, including SAHA, MS-275 and butyrate (Ruefli *et al.*, 2001; Rosato *et al.*, 2003b; Kurita-Ochiai *et al.*, 2003). Consequently, ROS levels were monitored in U937 and Jurkat cells exposed to 30 or 75 nM LAQ824. Exposure to either 30 or 75 nM LAQ824 for 2 hr induced similar increments in ROS levels in U937 cells (Fig 4A). However, ROS generation was observed after 30 min of treatment with 75 nM LAQ824 but only after 2 hr exposure to 30 nM LAQ824 (data not shown). Similar effects were detected in Jurkat cells treated with 50 nM LAQ824 where an early ROS peak was also observed (Figure 4A). To determine the functional contribution of the early increase in ROS to lethality, U937 and Jurkat cells were exposed to LAQ824 in the absence or presence of the free radical scavenger N-acetyl cysteine (NAC). As shown in Fig. 4A, co-exposure of cells to NAC blocked LAQ-induced ROS production. Moreover, treatment of either U937 (Figure 4B) or Jurkat cells (data not shown) with LAQ824 in the presence of NAC essentially abolished mitochondrial injury (i.e., loss of $\Delta\psi_m$) and apoptosis. Moreover, cells treated with LAQ824 + NAC displayed a marked reduction in activation of caspases-3,-8 and Bid, PARP degradation, and release of mitochondrial proteins into the cytoplasm (data not shown). Furthermore, cleavage of Bcl-2 and Bcl-xL and Mcl-1 down-regulation were essentially abrogated by NAC, suggesting these were secondary, caspase-dependent events. In contrast, XIAP expression was only modestly restored by NAC. The finding that both 30 and 75 nM LAQ824 concentrations induced a similar increase in ROS levels suggests that this event may be necessary but not sufficient for LAQ824-mediated lethality.

Functional role of XIAP and Mcl-1 down-regulation in LAQ824-induced lethality.

Studies were then undertaken to investigate the functional role of both XIAP and Mcl-1 down-regulation in LAQ824-mediated lethality. Time-course analysis of XIAP expression in U937 cells by Western blot demonstrated a marked reduction in protein expression following treatment of cells with 75 nM LAQ824, which approached ~90% at 48 h (Figure 5A). The presence of an XIAP cleavage fragment was also detected at later intervals (Fig. 5A), which may explain the partial restoration of protein levels by NAC (Fig. 4C). In contrast, 30 nM LAQ824 had no effect on XIAP expression. XIAP antiapoptotic activity is exerted in part by blocking the actions of caspases 3, -7 and -9 (Deveraux *et al.*, 1998). Consistently, 75 nM LAQ824-mediated XIAP down-regulation correlated closely with activation of caspases 9, -3 and -7, whereas no activation was observed in cells exposed to 30 nM LAQ824. Enforced expression of XIAP (Datta *et al.*, 2000) significantly blocked LAQ824-induced lethality at the 24 and 48-hr intervals ($P < 0.02$), suggesting that XIAP down-regulation plays an important functional role in LAQ824 lethality. LAQ824 effects on the transcriptional regulation of XIAP were then examined employing real time RT-PCR analysis (Figure 5C). LAQ824 resulted in pronounced transcriptional inhibition of XIAP gene expression, i.e. approximately 50% after 24 hours and 90% after 36-48 hours (Figure 5C). Moreover, levels of XIAP mRNA were only partially restored by blocking apoptosis with NAC, further demonstrating that LAQ824-induced XIAP mRNA down-regulation does not solely reflect a secondary, apoptosis-mediated event. In contrast, 30nM LAQ824 had no effect on XIAP expression at either the protein (Fig. 5A) or mRNA level (Fig. 5C).

Analysis of Mcl-1 expression showed dramatic down-regulation after 32 hours exposure to 75 nM (but not 30 nM) LAQ824 (Fig. 6A), accompanied by the appearance of a ~27 kDa

cleavage fragment as previously reported (Weng *et al.*, 2005), which was detectable after 24 hours exposure to LAQ824 (Fig. 6A). Subsequently, U937 cells stably expressing either the empty vector (U937/pCEP) or Mcl-1 (U937/Mcl-1) cDNAs were exposed to LAQ824 75 nM for 24-48 hours. As shown in Fig. 6B, U937/Mcl-1 cells displayed a significant reduction in the extent of apoptosis induced by 75 nM LAQ824 (Fig. 6B) which was also reflected by reduced activation of caspases 3, -7 and -9, and PARP degradation (Fig. 6C). Together, these results suggest that down-regulation of both antiapoptotic proteins through either transcriptional (e.g., XIAP) or primarily caspase-dependent mechanisms (e.g., Mcl-1) plays a significant role in the disparate apoptotic responses of U937 cells to low (30 nM) versus high (75 nM) LAQ824 concentrations.

Exposure of U937 cells to LAQ824 induces a dramatic increase in the level of the pro-apoptotic lipid second messenger ceramide. Because ceramide has been implicated in apoptosis induction in human leukemia cells (Jarvis *et al.*, 1994; Kurita-Ochiai *et al.*, 2003), U937 and Jurkat cells were treated with LAQ824 (U937: 30 nM and 75 nM; Jurkat: 50 nM) for various intervals, after which ceramide levels were monitored. As shown in Figure 7A, lethal concentrations of LAQ824 induced significant increases in ceramide levels in both U937 and Jurkat cells which were ~ 5-fold higher than controls at 24 h and ~ 15-fold higher after 48 hr. In contrast, 30 nM LAQ824 only minimally increased ceramide levels (Figure 7A), raising the possibility differential increases in ceramide levels may also contribute to the disparate effects of low versus high drug concentrations.

Generation of ceramide may proceed from either *de novo* synthesis or hydrolysis of sphingomyelin (Pettus *et al.*, 2002). Consequently, U937 cells were co-incubated with inhibitors targeting these pathways at different points. The *de novo* synthesis inhibitors fumonisin B1 and

myriocin exerted no effects on LAQ824-induced apoptosis. Similarly, the neutral-sphingomyelinase inhibitor GW4869 was also ineffective. In contrast, desipramine, an inhibitor of acidic-sphingomyelinase (ASM) (Pettus *et al.*, 2002) partially but significantly blocked LAQ824-mediated apoptosis (i.e., LAQ824 75 nM: 82.3 ± 2.1 vs. L75+desipramine: 52.6 ± 2.2 at 48 hr; $P < 0.01$; Figure 7B), suggesting that LAQ824-induced ceramide generation through the hydrolysis of sphingomyelin contributes functionally to the lethal effects of high concentrations of LAQ824. Finally, blockade of LAQ824-induced ROS by NAC essentially abrogated ceramide generation (Figure 7C), indicating that LAQ824-induced ROS generation leads to the acid sphingomyelinase generation of ceramide, and that the latter event represents an important functional mediator of LAQ824-induced lethality.

DISCUSSION

Whereas previous studies have demonstrated that HDACIs can induce differentiation and/or apoptosis in human leukemia cells (Vrana *et al.*, 1999; Rosato *et al.*, 2001; Rosato *et al.*, 2003b), the factors determining which of these alternative cell fates predominates remain largely unknown. In the case of LAQ824, the present results demonstrate that low concentrations of the drug led to cell cycle arrest at G_0/G_1 , followed by cellular maturation, whereas higher concentrations induced G_2/M arrest accompanied by pronounced mitochondrial injury and apoptosis. These findings are consistent with previous reports of HDACI-mediated tumor cell G_2M arrest and subsequent death in mitosis due to an aberrant G_2 checkpoint (Qiu *et al.*, 2000). Furthermore, both induction of $p21^{WAF1/CIP1}$ and generation of ROS represented a common response to low and high concentrations of LAQ824, although the latter phenomenon occurred earlier in cells exposed to lethal LAQ824 concentrations. However, in addition to increased ROS

generation, LAQ824-induced apoptosis was accompanied by pronounced down-regulation of XIAP (at the transcriptional level) and Mcl-1 (through post-transcriptional modifications) as well as the marked acid sphingomyelinase-dependent generation of ceramide. Although differentiation and apoptosis share certain features (e.g., induction of mitochondrial injury), there is evidence that in leukemia cells, these events are mutually exclusive (Selvakumaran *et al.*, 1994). It is therefore likely that when administered above threshold levels, LAQ824 triggers multiple events which culminate in apoptosis and prevent engagement of a differentiation program. It is important to note that while differentiation-induction by low LAQ824 concentrations resulted in a marked loss of clonogenic potential, high concentrations of LAQ824 were significantly more inhibitory, reflecting the pronounced increase in apoptosis.

Recent studies have highlighted the role that the extrinsic apoptotic pathway plays in HDACI-mediated lethality including up-regulation of TRAIL and TRAIL-death receptors DR4 and DR5 in several human leukemia cell lines (Insinga *et al.*, 2005;Nebbioso *et al.*, 2005;Guo *et al.*, 2004). However, activation of the extrinsic/receptor-mediated pathway did not play a significant role in LAQ824-mediated lethality in U937 cells, and in contrast to Jurkat cells, death receptor expression was not up-regulated by LAQ824, suggesting that the latter phenomenon is cell lineage-specific. Furthermore, the finding that Bcl-2 or Bcl-xL overexpression, by blocking the release of cytochrome c, AIF and Smac, substantially protected cells against LAQ824 lethality, strongly implicates the mitochondrial pathway (Donovan and Cotter, 2004) in LAQ824 lethality. In this regard, LAQ824-induced degradation of several Bcl-2 family proteins including Bcl-2, Bcl-xL and Mcl-1 which, when overexpressed, significantly protected cells from lethality, support the notion that their down-regulation, while largely secondary events, nevertheless contribute substantially to amplify the cell death process.

Although the mechanisms by which HDACIs induce cell death may vary considerably (Rosato and Grant, 2004), induction of oxidative injury represents a common theme. Notably, ROS generation was observed in both U937 and Jurkat cells exposed to lethal concentrations of LAQ824. Significantly, ROS production as well as all downstream events including mitochondrial injury, caspase activation and apoptosis, were blocked by the free radical scavenger NAC, indicating that oxidative injury represents a primary event in activation of the apoptotic cascade. It is also noteworthy that prevention of ROS generation by NAC blocked LAQ824-mediated induction of ceramide. This finding is consistent with evidence that ceramide generation represents an important downstream signaling event in cells experiencing oxidative damage and mitochondrial injury (Mansat-de Mas *et al.*, 1999). Unexpectedly, both low and high LAQ824 concentrations elicited similar increases in ROS levels, although these occurred earlier in the case of 75 nM LAQ824. The functional significance of the early induction of oxidative injury by high LAQ824 concentrations remains to be determined. The present results contrast with those involving the benzamide HDACI MS-275, in which leukemic cell apoptosis correlated closely with ROS generation (Rosato *et al.*, 2003b). This suggests that the functional significance of HDACI-induced ROS production in human leukemia cells may vary with the class of HDACI involved. Collectively, these findings indicate that LAQ824-mediated oxidative damage is necessary but not sufficient to trigger apoptosis in these cells, and that for this to occur, other events (e.g., XIAP/Mcl-1 down-regulation, ceramide generation, etc.) must supervene.

Studies performed utilizing U937 cells ectopically expressing either XIAP or Mcl-1, suggest that down-regulation of these proteins plays a significant functional role in LAQ824-induced lethality. For example, a clear correlation between LAQ824-induced XIAP down-

regulation and activation of target caspases 9, -3 and -7 was observed; conversely, enforced expression of XIAP blocked activation of these caspases. XIAP down-regulation has previously been reported in human leukemia cells exposed to HDACIs, notably MS-275 (Rosato *et al.*, 2003b), although the molecular mechanisms responsible for this phenomenon have not been explored in detail. The present results suggest that LAQ824-mediated down-regulation of XIAP levels primarily involves transcriptional repression, a phenomenon amplified by caspase-mediated degradation. It is well known that HDAC inhibitors, by modulating histone acetylation and remodeling chromatin architecture, regulate gene expression, which can involve both up- and down-regulation (Peart *et al.*, 2005). Furthermore, two major mechanisms have been implicated in XIAP degradation: ubiquitination and proteasomal degradation (Yang *et al.*, 2000) and/or caspase degradation (Johnson *et al.*, 2000). The finding that the antioxidant NAC partially blocked XIAP down-regulation by LAQ824 in association with diminished apoptosis suggests that caspase-dependent cleavage contributes to this phenomenon, although the possibility of enhanced proteasomal degradation cannot be excluded. On the other hand, results of Real-Time RT-PCR studies strongly suggest that transcriptional repression plays an important role in this phenomenon. Finally, the observation that only higher LAQ824 concentrations resulted in transcriptional repression and down-regulation of XIAP supports the notion that differential effects on XIAP contribute to disparate dose-responsive effects of LAQ824 in these cells. In contrast to XIAP, Mcl-1 down-regulation induced by higher LAQ824 concentrations primarily represented a secondary, caspase-mediated process, although it in all likelihood contributed to lethality. The importance of Mcl-1 in circumventing apoptosis in malignant hematopoietic cells has been documented (Moulding *et al.*, 2000). Furthermore, caspase 3-mediated Mcl-1 degradation promotes apoptosis by two mechanisms i.e., by reducing Mcl-1

expression levels and by generating an Mcl-1 C-terminal fragment with pro-apoptotic activity (Weng *et al.*, 2005). The C-terminal portion of Mcl-1 promotes cytochrome c release from the mitochondria by forming a heterodimer with tBid (Weng *et al.*, 2005). Similar observations have been reported in the case of Bcl-2 (Kirsch *et al.*, 1999), which also experienced cleavage in cells exposed to high concentrations of LAQ824. Thus, while these phenomena represent secondary events in LAQ824-induced apoptosis, both degradation and generation of pro-apoptotic Mcl-1 and Bcl-2 fragments may amplify the caspase cascade and contribute to the time-dependent increase in lethality.

Another factor implicated in the lethality of high LAQ824 concentrations is ceramide, a lipid second messenger involved in cellular responses to stress and apoptosis induction (Pettus *et al.*, 2002), including that generated by HDACIs such as butyrate and MS-275 (Kurita-Ochiai *et al.*, 2003; Maggio *et al.*, 2004). Significantly, only high concentrations of LAQ824 triggered pronounced increases in ceramide. Furthermore, inhibition of ceramide generation *via* A-SMase attenuated LAQ824-mediated lethality, arguing that increased ceramide generation plays a functional role in LAQ824-induced apoptosis. A-SMase is activated by several pro-apoptotic stimuli including induction of death receptors [i.e., CD95/FAS and TNF-R] (Gulbins and Grassme, 2002) and γ - and UV-radiation (Zhang *et al.*, 2001). Notably, LAQ824-mediated ceramide generation was dependent on early ROS generation. A close relationship between ROS and ceramide production has been characterized in several models including U937 cells exposed to daunorubicin and rat primary astrocytes (Mansat-de Mas *et al.*, 1999). It is unclear at present why increases in ROS induced by low LAQ824 concentrations failed to increase ceramide levels, while higher LAQ824 concentrations did so. One speculative possibility is that high concentrations of LAQ824 might interfere with the function of chaperones such as Hsp90

(Atadja *et al.*, 2004b), and thus enhance the degradation of proteins that inhibit ceramide generation. Alternatively, LAQ824 might lead to down-regulation of as yet to be determined genes with similar functions. In any case, the present studies suggest that multiple factors cooperate to disrupt leukemic cell differentiation and promote apoptosis by supra-threshold concentrations of LAQ824. Furthermore, these findings may have implications for the rational development of combination regimens involving this novel HDACI in hematologic malignancies.

References

Almenara J, Rosato R, and Grant S (2002) Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA). *Leukemia* **16**: 1331-1343.

Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, and Remiszewski S (2004a) Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824. *Cancer Res* **64**: 689-695.

Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, and Remiszewski S (2004b) Molecular and Cellular Basis for the Anti-Proliferative Effects of the HDAC Inhibitor LAQ824. *Novartis Found Symp* **259**: 249-266.

Cartee L, Smith R, Dai Y, Rahmani M, Rosato R, Almenara J, Dent P, and Grant S (2002) Synergistic Induction of Apoptosis in Human Myeloid Leukemia Cells by Phorbol 12-Myristate 13-Acetate and Flavopiridol Proceeds Via Activation of Both the Intrinsic and Tumor Necrosis Factor-Mediated Extrinsic Cell Death Pathways. *Mol Pharmacol* **61**: 1313-1321.

Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi N, Schlossman R, Richardson P, Griffin J, and Anderson KC (2003) NVP-LAQ824 Is a Potent Novel Histone Deacetylase Inhibitor With Significant Activity Against Multiple Myeloma. *Blood* **102**: 2615-2622.

Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, and Hardwick JM (1997) Conversion of Bcl-2 to a Bax-Like Death Effector by Caspases. *Science* **278**: 1966-1968.

Datta R, Oki E, Endo K, Biedermann V, Ren J, and Kufe D (2000) XIAP Regulates DNA Damage-Induced Apoptosis Downstream of Caspase-9 Cleavage. *J Biol Chem* **275**: 31733-31738.

Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, and Reed JC (1998) IAPs Block Apoptotic Events Induced by Caspase-8 and Cytochrome c by Direct Inhibition of Distinct Caspases. *EMBO J* **17**: 2215-2223.

Donovan M and Cotter TG (2004) Control of Mitochondrial Integrity by Bcl-2 Family Members and Caspase-Independent Cell Death. *Biochim Biophys Acta* **1644**: 133-147.

Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, and Bhalla K (2003) Histone Deacetylase Inhibitor LAQ824 Down-Regulates Her-2 and Sensitizes Human Breast Cancer Cells to Trastuzumab, Taxotere, Gemcitabine, and Etoposide. *Mol Cancer Ther* **2**: 971-984.

Gray SG and Teh BT (2001) Histone Acetylation/Deacetylation and Cancer: an "Open" and "Shut" Case? *Curr Mol Med* **1**: 401-429.

Gulbins E and Grassme H (2002) Ceramide and Cell Death Receptor Clustering. *Biochim Biophys Acta* **1585**: 139-145.

Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, and Bhalla K (2004) Cotreatment With Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells. *Cancer Res* **64**: 2580-2589.

Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, and Pelicci PG (2005) Inhibitors of Histone Deacetylases Induce Tumor-Selective Apoptosis Through Activation of the Death Receptor Pathway. *Nat Med* **11**: 71-76.

Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, and Grant S (1994) Induction of Apoptotic DNA Damage and Cell Death by Activation of the Sphingomyelin Pathway. *Proc Natl Acad Sci U S A* **91**: 73-77.

Johnson DE, Gastman BR, Wieckowski E, Wang GQ, Amoscato A, Delach SM, and Rabinowich H (2000) Inhibitor of Apoptosis Protein HILP Undergoes Caspase-Mediated Cleavage During T Lymphocyte Apoptosis. *Cancer Res* **60**: 1818-1823.

Kirsch DG, Doseff A, Chau BN, Lim DS, Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA, and Hardwick JM (1999) Caspase-3-Dependent Cleavage of Bcl-2 Promotes Release of Cytochrome c. *J Biol Chem* **274**: 21155-21161.

Kurita-Ochiai T, Amano S, Fukushima K, and Ochiai K (2003) Cellular Events Involved in Butyric Acid-Induced T Cell Apoptosis. *J Immunol* **171**: 3576-3584.

Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, and Grant S (2004) The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically With Fludarabine to Induce Apoptosis in Human Leukemia Cells. *Cancer Res* **64**: 2590-2600.

Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaieb A, D'orgeix AD, Laurent G, and Jaffrezou JP (1999) Implication of Radical Oxygen Species in Ceramide Generation, C-Jun N-Terminal Kinase Activation and Apoptosis Induced by Daunorubicin. *Mol Pharmacol* **56**: 867-874.

Moulding DA, Giles RV, Spiller DG, White MR, Tidd DM, and Edwards SW (2000) Apoptosis Is Rapidly Triggered by Antisense Depletion of MCL-1 in Differentiating U937 Cells. *Blood* **96**: 1756-1763.

Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, and Altucci L (2005) Tumor-Selective Action of HDAC Inhibitors Involves TRAIL Induction in Acute Myeloid Leukemia Cells. *Nat Med* **11**: 77-84.

Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, and Bhalla K (2003) Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-Sensitive or -Refractory Chronic Myelogenous Leukemia-Blast Crisis Cells. *Cancer Res* **63**: 5126-5135.

Pearl MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, and Johnstone RW (2005) Identification and Functional Significance of Genes Regulated by Structurally Different Histone Deacetylase Inhibitors. *Proc Natl Acad Sci U S A* **102**: 3697-3702.

Pettus BJ, Chalfant CE, and Hannun YA (2002) Ceramide in Apoptosis: an Overview and Current Perspectives. *Biochim Biophys Acta* **1585**: 114-125.

Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, and Gabrielli BG (2000) Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That Is Defective in Tumor Cells. *Mol Biol Cell* **11**: 2069-2083.

Rosato RR, Almenara JA, Dai Y, and Grant S (2003a) Simultaneous Activation of the Intrinsic and Extrinsic Pathways by Histone Deacetylase (HDAC) Inhibitors and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Induces Mitochondrial Damage and Apoptosis in Human Leukemia Cells. *Mol Cancer Ther* **2**: 1273-1284.

Rosato RR, Almenara JA, and Grant S (2003b) The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells Through a Process Regulated by Generation of Reactive Oxygen Species and Induction of P21CIP1/WAF1 1. *Cancer Res* **63**: 3637-3645.

Rosato RR, Dai Y, Almenara JA, Maggio SC, and Grant S (2004) Potent Antileukemic Interactions Between Flavopiridol and TRAIL/Apo2L Involve Flavopiridol-Mediated XIAP Downregulation. *Leukemia* **18**: 1780-1788.

Rosato RR and Grant S (2004) Histone Deacetylase Inhibitors in Clinical Development. *Expert Opin Investig Drugs* **13**: 21-38.

Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, and Grant S (2001) Evidence of a Functional Role for the Cyclin-Dependent Kinase-Inhibitor P21WAF1/CIP1/MDA6 in Promoting Differentiation and Preventing Mitochondrial Dysfunction and Apoptosis Induced by Sodium Butyrate in Human Myelomonocytic Leukemia Cells (U937). *Int J Oncol* **19**: 181-191.

Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, and Johnstone RW (2001) The Histone Deacetylase Inhibitor and Chemotherapeutic Agent Suberoylanilide Hydroxamic Acid (SAHA) Induces a Cell-Death Pathway Characterized by Cleavage of Bid and Production of Reactive Oxygen Species. *Proc Natl Acad Sci U S A* **98**: 10833-10838.

Selvakumaran M, Reed JC, Liebermann D, and Hoffman B (1994) Progression of the Myeloid Differentiation Program Is Dominant to Transforming Growth Factor-Beta 1-Induced Apoptosis in M1 Myeloid Leukemic Cells. *Blood* **84**: 1036-1042.

Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, and Marks PA (2005) Role of Thioredoxin in the Response of Normal and Transformed Cells to Histone Deacetylase Inhibitors. *Proc Natl Acad Sci U S A* **102**: 673-678.

Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, and Grant S (1999) Induction of Apoptosis in U937 Human Leukemia Cells by Suberoylanilide

Hydroxamic Acid (SAHA) Proceeds Through Pathways That Are Regulated by Bcl-2/Bcl-XL, C-Jun, and P21CIP1, but Independent of P53. *Oncogene* **18**: 7016-7025.

Weng C, Li Y, Xu D, Shi Y, and Tang H (2005) Specific Cleavage of MCL-1 by Caspase-3 in Trail-Induced Apoptosis in Jurkat Leukemia T Cells. *J Biol Chem* **280**: 10491-10500.

Yang Y, Fang S, Jensen JP, Weissman AM, and Ashwell JD (2000) Ubiquitin Protein Ligase Activity of IAPs and Their Degradation in Proteasomes in Response to Apoptotic Stimuli. *Science* **288**: 874-877.

Yin DX and Schimke RT (1995) BCL-2 Expression Delays Drug-Induced Apoptosis but Does Not Increase Clonogenic Survival After Drug Treatment in HeLa Cells. *Cancer Res* **55**: 4922-4928.

Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, and Schrupp DS (2002) Modulation of P53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228. *J Natl Cancer Inst* **94**: 504-513.

Zhang Y, Mattjus P, Schmid PC, Dong Z, Zhong S, Ma WY, Brown RE, Bode AM, Schmid HH, and Dong Z (2001) Involvement of the Acid Sphingomyelinase Pathway in Uva-Induced Apoptosis. *J Biol Chem* **276**: 11775-11782.

Footnotes This work was supported by awards CA-63753, CA-93738, CA-100866 (S.G.) and CA-61774 (S.S.), from the National Cancer Institute, award 6045-03 from the Leukemia and Lymphoma Society of America, an award from the V Foundation, and awards DAMD-17-03-1-0209 (S.G.) and DAMD-17-02-1-0060 (S.S.) from the Department of Defense.

LEGENDS OF FIGURES

Fig. 1 LAQ824 induces dose-dependent growth arrest or cell death in human leukemia cells. *A*, U937 cells in logarithmic phase were suspended at 2.5×10^5 cells/ml in the presence of LAQ824 at the indicated concentrations, and assayed at 24, 48 and 72 h by monitoring the number of cells post-treatment employing a Beckman Coulter Counter. *B*, The extent of apoptosis was determined by annexin V/PI analysis as described in Methods. *C*, Western blot analysis of lysates of U937 cells exposed to 30nM or 75nM LAQ824 collected at the indicated time intervals. After treatment, cells were pelleted, lysed and 30 μ g of protein separated by SDS-PAGE as described in Methods. Blots were then probed with the indicated antibodies directed against PARP, caspases 3 and -8 and Bid. Blots were subsequently stripped and probed with antibodies directed against tubulin to ensure equivalent loading and transfer. The results of a representative study are shown; two additional experiments yielded similar results. *D*, lysates from U937 cells exposed to either 30 or 75nM LAQ824 for 24 hours were analyzed by western blot as described above. *E*, after incubation with the indicated concentration of LAQ824 for 72 h, the percentage of U937 cells expressing the surface differentiation markers Cd11a and Cd11b was determined by flow cytometry as described in Methods. Values represent the means \pm SD for three separate experiments performed in triplicate. *F*, U937 cells were exposed to either 30 nM or 75 nM LAQ824 for the indicated intervals after which cells were washed free of drugs and plated in soft agar as described in Methods. Colonies, consisting of groups of ≥ 50 cells, were scored after 10-12 days.

Fig. 2 LAQ824-induced cell death does not involve activation of the extrinsic, receptor-mediated apoptotic pathway in U937 cells. *A*, U937 and Jurkat cells were co-incubated with LAQ824

(75nM and 50nM respectively) in the presence or absence of either anti-TRAIL or anti-FAS-L antibodies after which the percentage of apoptotic cells was monitored by Annexin V/PI staining. *B*, Jurkat and U937 cells were treated as above after which expression of DR5 was monitored by flow cytometry as described in Methods. Results are representative of 3 separate studies.

Fig. 3 Effects of LAQ824 exposure on mitochondrial integrity and anti-apoptotic proteins. *A*, U937 cells were incubated with either 30nM or 75nM LAQ824 for the indicated intervals after which the percentage of cells exhibiting a loss of $\Delta\psi_m$ was determined by flow cytometry as described in Methods. Values represent the means for three separate experiments \pm S.E.M. *B-C*, U937 cells were treated as in (*A*), cells were pelleted, lysed, and protein extracted from either the cytosolic S-100 fraction [AIF, cytochrome c, Smac; (*B*)] or whole cell lysates [Bcl-2, Bcl-xL, Mcl-1, and XIAP; (*C*)]. In each case, 30 μ g of protein were separated by SDS-PAGE, after which blots were probed with the corresponding antibodies. Blots were subsequently stripped and probed with antibodies directed against tubulin to ensure equivalent loading and transfer. The results of a representative study are shown; two additional experiments yielded similar results. *D*, U937 cells transfected with an empty vector (*EV*) or plasmids encoding Bcl-2 or Bcl-X_L were incubated with 75nM LAQ824 for 24h and 48h, after which the percentage of annexinV/PI cells was determined as described. Values represent the means \pm SD for three separate experiments performed in triplicate. *: significantly less than values obtained for empty vector control cells, $P > 0.05$ and > 0.01 for L24 and L48 respectively.

Fig. 4 Exposure of U937 cells to LAQ824 induces the generation of reactive oxygen species. *A*, Both U937 (upper panels) and Jurkat (lower panels) cells were incubated with LAQ824 (30 and 75nM in U937 cells; 50nM in Jurkat cells) \pm the free radical scavenger NAC (15 mM) for various intervals as indicated, after which they were labeled with an oxidative-sensitive dye

(H₂DCFDA) and analyzed by flow cytometry to determine the percentage of cells displaying an increase in ROS production (reflected by a *rightward shift* of the histogram). *B*, U937 cells were treated for 48 h with LAQ824 as above in the absence or presence of 15 mM NAC. At the end of the incubation period, the percentage of cells exhibiting loss of $\Delta\psi_m$ or apoptosis (annexinV/PI⁺) was determined as described in Methods. Values represent the means \pm SD for three separate experiments performed in triplicate. *: significantly less than values obtained for cells treated with LAQ824 in the absence of NAC, $P < 0.001$. *C*, In parallel, whole lysates from U937 cells incubated with 75nM LAQ824 for 48h in the presence (L48/N) or absence (L48) of NAC were prepared and analyzed by Western blot as described. In each case, 30 μ g of protein were separated by SDS-PAGE, after which blots were probed with the corresponding antibodies. Blots were subsequently stripped and re-probed with antibodies directed against tubulin to ensure equivalent loading and transfer. The results of a representative study are shown; two additional experiments yielded similar results. L: incubated in the presence of LAQ824; L48/N: incubated with LAQ824 for 48h in the presence of NAC.

Fig. 5 Role of XIAP down-regulation in LAQ824-induced lethality. *A*, U937 cells were exposed to either 30nM or 75nM LAQ824 for the indicated intervals after which cells were collected, lysed and analyzed by WB. In each case, 30 μ g of protein were separated by SDS-PAGE, blotted and probed with the corresponding antibodies. The results of a representative study are shown; two additional experiments yielded similar results. Values shown represent the percentage protein expression determined by densitometry relative to control values (100%). *B*, Both U937 cells overexpressing a cDNA encoding XIAP (U937/XIAP) or the corresponding empty vector (U937/EV) cells were exposed for 24 and 48 hours to 75 nM LAQ824 after which the percentage of apoptotic cells (annexinV/PI⁺) was determined by flow cytometry as described in Methods.

Values represent the means \pm SD for three separate experiments performed in triplicate. *C*, U937 cells were exposed to LAQ824 as above, after which expression of XIAP mRNA and 18S rRNA levels (used as a normalization parameter to ensure equivalent loading as specified by the manufacturer) were monitored by RT-PCR as described in methods. Values for each condition are expressed as ng of specific XIAP mRNA/ μ g or total RNA. Values represent the means \pm S.D. for three separate experiments performed in triplicate.

Fig.6 Mcl-1 degradation contributes to LAQ824-induced lethality. *A*, U937 cells were exposed to either 30nM or 75nM LAQ824 for the indicated intervals after which cells were collected, lysed and analyzed by WB. In each case, 30 μ g of protein were separated by SDS-PAGE, blotted and probed with the corresponding antibodies. The results of a representative study are shown; two additional experiments yielded similar results. *B*, Both U937 cells overexpressing a cDNA encoding for Mcl-1 (U937/Mcl-1) or the corresponding empty vector (U937/pCEP) cells were exposed for 24 and 48 hours to 75 nM LAQ824 after which the percentage of apoptotic cells (annexinV/PI⁺) was determined by flow cytometry as described in Methods. Values represent the means \pm SD for three separate experiments performed in triplicate. *C*, WB analysis of lysates from U937/pCEP or U937/Mcl-1 cells; cells were exposed to 75nM LAQ824 for the indicated intervals after which they were collected, lysed and 30 μ g of protein separated by SDS-PAGE, blotted and probed with the corresponding antibodies. The results of a representative study are shown; two additional experiments yielded similar results.

Fig. 7 Exposure of U937 cells to LAQ824 results in the acid sphingomyelinase-dependent increase in ceramide levels. *A*, Both U937 and Jurkat cells were exposed to 30-75 nM and 50 nM LAQ824 respectively for the indicated intervals after which ceramide levels, normalized to levels of total phospholipids, were compared with those of untreated control cells. Values are

expressed as fold increases over control levels and represent the means for three separate determinations \pm S.D. *: significantly greater than values for U937 cells exposed to 30nM LAQ824; $P < 0.01$. *B*, U937 cells were incubated for either 24 or 48 hours with LAQ824 in the absence (L75) or the presence of various inhibitors of ceramide synthesis (FU: 25 μ M fumonisin B1; MY: 10 μ M myriocin; GW: 10 μ M GW4869; DE: 30 μ M desipramine) after which apoptosis (annexinV/PI positivity) was monitored as described in Methods. *: significantly lower than values for U937 cells exposed to 75nM LAQ824; $P < 0.05$. *C*, U937 cells were co-exposed to 75 nM LAQ824 in the presence or absence (L75) of the free-radical scavenger NAC or the acid sphingomyelinase inhibitor desipramine (Des) for 24 or 48 hours after which ceramide levels were determined as described in Methods. Values represent the means \pm SD for three separate experiments performed in triplicate. *: significantly lower than values for U937 cells exposed to 75nM LAQ824; $P < 0.05$.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

